ES2156357T3 - Antagonistas oxadiazol y tiadiazol del receptor muscarinico. - Google Patents

Antagonistas oxadiazol y tiadiazol del receptor muscarinico.

Info

Publication number
ES2156357T3
ES2156357T3 ES97902337T ES97902337T ES2156357T3 ES 2156357 T3 ES2156357 T3 ES 2156357T3 ES 97902337 T ES97902337 T ES 97902337T ES 97902337 T ES97902337 T ES 97902337T ES 2156357 T3 ES2156357 T3 ES 2156357T3
Authority
ES
Spain
Prior art keywords
rent
antagonists
tiadiazol
oxadiazol
heteroaril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97902337T
Other languages
English (en)
Inventor
Alexander Roderick Mackenzie
Anthony Wood
Robert John Bass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2156357T3 publication Critical patent/ES2156357T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN COMPUESTO DE FORMULA (I), EN LA QUE R 1 ES ALQUILO C 1 -C 6 , HALO - (ALQUILO C 1 -C 6 ), CICLOALQUILO C 3 -C 7 , ALQUINILO C 2 -C 6 , HIDROXI - ALQUINILO C 2 -C 6 , ALCOXI (C 1 C 4 )-(ALQUINILO C 2 -C 6 ), ARILO, ARIL - (ALQUILO C 1 -C SU B,4 ), HETEROARILO O HETEROARIL - (ALQUILO C 1 C 4 ); R 2 ES H O ALQUILO C 1 -C 4 ; R 3 ES ARILO, HETEROARILO, 2,3 - DIHIDROBENZOFURANILO O CICLOALQUILO C 4 -C 7; X ES O O S; E Y ES UN ENLACE DIRECTO; CH 2 -, -(CH 2 ) 2 - O -CH 2 O-; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO. LOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR MUSCARINICO UTILES EN EL TRATAMIENTO DE, POR EJEMPLO, EL SINDROME DEL INTESTINO IRRITABLE Y LA INCONTINENCIA URINARIA. LOS COMPUESTOS TAMBIEN SON UTILES COMO POTENCIADORES DE LA COGNICION.
ES97902337T 1996-02-22 1997-02-04 Antagonistas oxadiazol y tiadiazol del receptor muscarinico. Expired - Lifetime ES2156357T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9603755.1A GB9603755D0 (en) 1996-02-22 1996-02-22 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2156357T3 true ES2156357T3 (es) 2001-06-16

Family

ID=10789217

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97902337T Expired - Lifetime ES2156357T3 (es) 1996-02-22 1997-02-04 Antagonistas oxadiazol y tiadiazol del receptor muscarinico.

Country Status (43)

Country Link
US (1) US5977142A (es)
EP (1) EP0885218B1 (es)
JP (1) JP3148252B2 (es)
KR (1) KR100315934B1 (es)
CN (1) CN1089340C (es)
AP (1) AP751A (es)
AR (1) AR005916A1 (es)
AT (1) ATE200899T1 (es)
AU (1) AU712230B2 (es)
BG (2) BG63971B1 (es)
BR (1) BR9707733A (es)
CA (1) CA2247164C (es)
CO (1) CO4650040A1 (es)
CZ (1) CZ292650B6 (es)
DE (1) DE69704701T2 (es)
DK (1) DK0885218T3 (es)
DZ (1) DZ2181A1 (es)
ES (1) ES2156357T3 (es)
GB (1) GB9603755D0 (es)
GR (1) GR3036032T3 (es)
HK (1) HK1018274A1 (es)
HN (1) HN1997000020A (es)
HR (1) HRP970098B1 (es)
HU (1) HUP9900501A3 (es)
ID (1) ID16642A (es)
IL (1) IL125413A (es)
IS (1) IS4803A (es)
MY (1) MY129729A (es)
NO (1) NO313414B1 (es)
NZ (1) NZ331039A (es)
OA (1) OA10838A (es)
PE (1) PE42798A1 (es)
PL (1) PL186879B1 (es)
PT (1) PT885218E (es)
RU (1) RU2162848C2 (es)
SK (1) SK283461B6 (es)
TN (1) TNSN97039A1 (es)
TR (1) TR199801644T2 (es)
TW (1) TW492961B (es)
UA (1) UA61068C2 (es)
WO (1) WO1997030994A1 (es)
YU (1) YU35698A (es)
ZA (1) ZA971513B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
WO2008017827A2 (en) * 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
WO2008023157A1 (en) * 2006-08-21 2008-02-28 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as m3-receptor modulators
WO2008096093A1 (en) * 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
GB0702385D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702414D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd Oxazole and thiazole derivatives and their uses 2
MX2009008364A (es) * 2007-02-07 2009-08-20 Astrazeneca Ab Sal de napadisilato de un antagonista m3 muscarinico.
GB0702382D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New salt
GB0702416D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
AU2008215924B2 (en) * 2007-02-15 2011-04-21 Pulmagen Therapeutics (Synergy) Limited Heterocyclic derivatives as M3 muscarinic receptors
WO2009098453A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010018352A1 (en) * 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
JP2014065387A (ja) * 2012-09-25 2014-04-17 Showa Corp 自動二輪車の車高調整装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
IL88846A0 (en) * 1988-01-08 1989-07-31 Merck Sharp & Dohme Lipophilic oxadiazoles,their preparation and pharmaceutical compositions containing them
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
AU3171493A (en) * 1991-12-31 1993-07-28 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
TW360653B (en) * 1995-03-01 1999-06-11 Janssen Pharmaceutica Nv A oxadiazole compound having colon motility stimulating properties, its preparation process and its pharmaceutical composition

Also Published As

Publication number Publication date
HUP9900501A2 (hu) 1999-06-28
KR19990087143A (ko) 1999-12-15
RU2162848C2 (ru) 2001-02-10
NO983871D0 (no) 1998-08-21
TW492961B (en) 2002-07-01
US5977142A (en) 1999-11-02
YU35698A (sh) 1999-07-28
EP0885218A1 (en) 1998-12-23
CA2247164A1 (en) 1997-08-28
WO1997030994A1 (en) 1997-08-28
KR100315934B1 (ko) 2002-03-21
PE42798A1 (es) 1998-08-18
CZ267898A3 (cs) 1999-08-11
JP3148252B2 (ja) 2001-03-19
IS4803A (is) 1998-07-21
HUP9900501A3 (en) 2001-02-28
IL125413A (en) 2002-09-12
EP0885218B1 (en) 2001-05-02
GR3036032T3 (en) 2001-09-28
TNSN97039A1 (fr) 2005-03-15
DZ2181A1 (fr) 2002-12-01
AR005916A1 (es) 1999-07-21
CN1089340C (zh) 2002-08-21
AU1601497A (en) 1997-09-10
ATE200899T1 (de) 2001-05-15
DE69704701T2 (de) 2001-08-16
CO4650040A1 (es) 1998-09-03
AP751A (en) 1999-07-12
NO313414B1 (no) 2002-09-30
BG63971B1 (bg) 2003-08-29
HK1018274A1 (en) 1999-12-17
GB9603755D0 (en) 1996-04-24
DK0885218T3 (da) 2001-05-28
AP9700930A0 (en) 1997-04-30
ZA971513B (en) 1998-08-21
CZ292650B6 (cs) 2003-11-12
IL125413A0 (en) 1999-03-12
UA61068C2 (en) 2003-11-17
JPH11504051A (ja) 1999-04-06
ID16642A (id) 1997-10-23
HRP970098A2 (en) 1999-04-30
NZ331039A (en) 1999-10-28
MY129729A (en) 2007-04-30
OA10838A (en) 2001-08-13
PT885218E (pt) 2001-08-30
TR199801644T2 (xx) 1998-11-23
NO983871L (no) 1998-08-21
PL328633A1 (en) 1999-02-15
CA2247164C (en) 2004-11-16
AU712230B2 (en) 1999-11-04
DE69704701D1 (de) 2001-06-07
BR9707733A (pt) 1999-07-27
CN1211981A (zh) 1999-03-24
HRP970098B1 (en) 2001-12-31
SK283461B6 (sk) 2003-08-05
PL186879B1 (pl) 2004-03-31
HN1997000020A (es) 1997-06-05
SK112398A3 (en) 2000-04-10
BG102699A (en) 1999-09-30

Similar Documents

Publication Publication Date Title
ES2156357T3 (es) Antagonistas oxadiazol y tiadiazol del receptor muscarinico.
FI943542A0 (fi) Trisyklisiä bentsatsepiineja, jotka ovat vasopressiiniantagonisteja
SE8503680D0 (sv) Indolderivat
DE59308619D1 (de) Germicide wirkstoffkombinationen
PE20000339A1 (es) Biciclo [2.2.1] heptanos y compuestos relacionados
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
PT1178045E (pt) Derivados de azaindole-etilamina como agentes de ligacao de receptores de acetilcolina nicotinicos
NO20012194D0 (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
ATE228364T1 (de) Indolalkaloide als antientzündliche wirkstoffe
PH30831A (en) Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia.
GB9000305D0 (en) Anticholinergic agents
PE87998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
ES2125481T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor de 5-ht4.
EA199900684A1 (ru) Производные иминоазаантрациклинона для лечения амилоидоза
ATE132486T1 (de) Pyrrolidin-dionderivate
CO4910154A1 (es) Derivados de espiro-piperidina y su uso como agentes tera- peuticos
DE69104646T2 (de) 2-Fluorneplanocin A und seine Herstellung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 885218

Country of ref document: ES